As researchers develop novel therapies based on inducing specific cells to do specific things, getting the right message to the right group of cells at the right time remains a major challenge. The use of light to communicate with cells has been restricted by its limited ability to pass through tissues. Now researchers at the Wellman Center for Photomedicine at Massachusetts General Hospital have developed a way to deliver a light signal to specific tissues deep within the body. They describe their accomplishment in the current issue of Nature Photonics.
"Scientists only began investigating light-activated therapy a few years ago, but it is generating huge interest," says Wellman investigator Seok Hyun (Andy) Yun, PhD, senior author of the study. "One of the best known example is use of optogenetics – activation or deactivation of brain cells by illumination with different colors of light – to treat brain disorders. But how to deliver light deep within the brain or other tissues has been a common problem. The implant we have developed may help solve this problem."
Light passing through an optical fiber (left) can either carry in a signal that stimulates the activity of cells embedded in the hydrogel implant or bring back a signal generated by cells responding to something in their environment. (Harvard Bio-Optics Lab/Wellman Center for Photomedicine, Mass. General Hospital)
Called a light-guiding hydrogel, the implant is constructed from a polymer-based scaffolding capable of supporting living cells and contains cells genetically engineered either to carry out a specific activity in response to light or to emit light in response to a particular metabolic signal. An optical fiber connects the implant to either an external light source or a light detector.
The investigators first determined the properties of the hydrogel scaffolding – including transparency, flexibility and stability – that would be most appropriate for delivering or detecting a light signal. After determining how many cells could be implanted into the hydrogel without significantly reducing its ability to transmit a light signal, they developed and tested in mice two different systems, both involving implantation of a 4-centimeter hydrogel beneath the animal's skin.
The first system's implants contained cells genetically engineered to express light-emitting green fluorescent protein (GFP) upon contact with a toxin. After confirming in vitro the hydrogels' response to nanoparticles containing the toxic metal cadmium, the researchers implanted the hydrogels beneath the skin of three groups of mice. One group was then injected with the cadmium nanoparticles, the second received nanoparticles encased in a polymer shell that shielded cells from the toxin, and the third received a control saline injection. The implants only produced a GFP-signal in response to the unshielded nanoparticles, indicating their ability to sense a change – in this instance the presence of a toxin – in the cellular environment.
To investigate a possible therapeutic application for the system, the investigators used a hydrogel implant containing cells that respond to blue light by producing glucagon-like peptide-1 (GLP-1), a protein playing an essential role in glucose metabolism. After the implants were placed under the skin of mice with diabetes, the blue light signal was delivered for 12 hours. A day and a half later – 48 hours after the implant – the animals that received the light signal had double the level of GLP-1 in their blood, along with significantly better results in a glucose tolerance test, than did implanted mice not treated with light.
"This work combines several existing technologies well known in their respective fields – such as drug delivery, genetic engineering, biomaterial science, and photonics – to build a new implant system that enables the delivery of photomedicine deep in the body," says Yun, an associate professor of Dermatology at Harvard Medical School and director of the Harvard Bio-Optics Lab. "This is the first time anyone has shown the ability to talk optically – by means of light – with cells deep within the body, both to sense the presence of a toxin and to deliver a cell-based therapy."
The researchers add that future studies should investigate how changing the shape and structure of the hydrogel can improve the implant's light-guiding properties, ways to improve the production and delivery of a therapeutic protein, how the immune system would react to long-term implantation and ways to deliver or detect the light signal that would not require passing a fiber through the skin.
Myunghwan Choi, PhD, of the Wellman Center at MGH is lead author of the Nature Photonics article. Additional co-authors are Jin Woo Choi, Sedat Nizamoglu, and Sei Kwang Hahn, PhD, Wellman Center; and Seonghoon Kim, Korea Advanced Institute of Science and Technology. Support for the study includes National Institutes of Health grant R21 EB013761, National Science Foundation grant ECS-1101947 and Department of Defense grant FA9550-10-1-0537.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
Sue McGreevey, firstname.lastname@example.org, 617 724-2764